Scholarlink

Introduction <p>Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patients.</p> Methods <p>A retrospective cohort analysis was conducted using the TriNetX database from 2015 to 2024. Breast cancer patients were categorized into two groups: AI users (anastrozole, exemestane, or letrozole) and tamoxifen users. A propensity score matching (1:1) adjusted for demographics, comorbidities, concurrent therapies, and lab values. The incidence of AF was assessed at 1, 5, and 10-years post-treatment initiation.</p> Results <p>The study included 220,552 AI users and 73,388 tamoxifen users before matching, with 54,175 patients in each group after matching. At 1&#xa0;year, AI users had a higher risk of AF (0.5% vs. 0.4%, RR: 1.36, <i>p</i> = 0.001). At 5&#xa0;years, AF incidence remained higher in the AI group (1.2% vs. 1.1%, RR: 1.13, <i>p</i> = 0.035).However at 10&#xa0;years, the difference in AF risk between the two groups was no longer significant (1.6% vs. 1.5%, RR: 1.05, <i>p</i> = 0.295).</p> Conclusion <p>AI use is associated with a higher risk of AF than tamoxifen in the first 5&#xa0;years of treatment, but the risk equalizes at 10&#xa0;years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Atrial fibrillation in breast cancer therapy: does tamoxifen confer a lower risk than aromatase inhibitors?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月31日

查看全文
  • Patrick A. Kwaah,
  • Samuel A. Mensah,
  • Emmanuel A. Agyemang,
  • Joseph S. Kekrebesi,
  • Daniil Katkov,
  • Abraham Carboo,
  • Grace Appah,
  • Hamza A. Rashid,
  • Jennifer M. Kwan

摘要

Introduction

Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patients.

Methods

A retrospective cohort analysis was conducted using the TriNetX database from 2015 to 2024. Breast cancer patients were categorized into two groups: AI users (anastrozole, exemestane, or letrozole) and tamoxifen users. A propensity score matching (1:1) adjusted for demographics, comorbidities, concurrent therapies, and lab values. The incidence of AF was assessed at 1, 5, and 10-years post-treatment initiation.

Results

The study included 220,552 AI users and 73,388 tamoxifen users before matching, with 54,175 patients in each group after matching. At 1 year, AI users had a higher risk of AF (0.5% vs. 0.4%, RR: 1.36, p = 0.001). At 5 years, AF incidence remained higher in the AI group (1.2% vs. 1.1%, RR: 1.13, p = 0.035).However at 10 years, the difference in AF risk between the two groups was no longer significant (1.6% vs. 1.5%, RR: 1.05, p = 0.295).

Conclusion

AI use is associated with a higher risk of AF than tamoxifen in the first 5 years of treatment, but the risk equalizes at 10 years. Long-term hormonal therapy has an increased risk of AF, highlighting the need for ongoing monitoring and management of risk factors.